Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
Adrianus J. de Langen(Dutch Cancer Society), Melissa L. Johnson(Tennessee Oncology), Julien Mazières(Centre Hospitalier Universitaire de Toulouse), Anne‐Marie C. Dingemans(Erasmus MC Cancer Institute), Giannis Mountzios(Henry Dunant Hospital), Miklos Pless(Kantonsspital Winterthur), Jürgen Wolf(University Hospital Cologne), Martin Schüler, H. Léna(Centre Hospitalier Universitaire de Rennes), Ferdinandos Skoulidis(The University of Texas MD Anderson Cancer Center), Yasuto Yoneshima(Kyushu University Hospital), Sang‐We Kim(Asan Medical Center), Helena Linardou(Metropolitan Hospital), Silvia Novello(University of Turin), Anthonie J. van der Wekken(University of Groningen), Yuanbin Chen(Hematology Oncology Consultants), Solange Peters(University Hospital of Lausanne), Enriqueta Felip(Vall d'Hebron Hospital Universitari), Benjamin Solomon(Peter MacCallum Cancer Centre), Suresh S. Ramalingam(Emory University), Christophe Dooms(KU Leuven), Colin R. Lindsay(University of Manchester), Carlos Gil Ferreira, Normand Blais(Centre Hospitalier de l’Université de Montréal), Cynthia C. Obiozor(Amgen (United States)), Yang Wang(Amgen (United States)), Bhakti Mehta(Amgen (United States)), Tracy Varrieur(Amgen (United States)), Gataree Ngarmchamnanrith(Amgen (United States)), Björn Stollenwerk(Amgen (Switzerland)), David Waterhouse(Oncology Hematology Care), Luis Paz‐Ares(Hospital Universitario 12 De Octubre)
Cited by 554Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis